1. A strip winding for a transformer, comprising:
a plurality of winding modules each having a strip conductor which is wound around a winding axis;
at least two axially adjacent winding segments, each winding segment being formed by at least two radially adjacent winding modules among the plurality of winding modules;
at least one cooling channel running in the axial direction between at least two of the radially adjacent winding modules; and
connecting conductors configured to connect the winding modules electrically in series,
wherein at least one of the connecting conductors is guided at least sectionally along an axial extent of the cooling channel through the cooling channel.
2. The strip winding as claimed in claim 1, wherein at least one of the connecting conductors includes an end-lead rail which is guided through the cooling channel.
3. The strip winding as claimed in claim 1, wherein at least two of the connecting conductors are electrically connected on an end face of the strip winding.
4. A transformer comprising:
a transformer core;
at least one strip winding as claimed in claim 1 as a low-voltage winding; and
at least one further DC-isolated winding as a high-voltage winding.
5. The transformer as claimed in claim 4, wherein the transformer has a three-phase configuration.
6. The strip winding as claimed in claim 2, wherein at least two of the connecting conductors are electrically connected on an end face of the strip winding.
7. A transformer comprising:
a transformer core;
at least one strip winding as claimed in claim 2 as a low-voltage winding; and
at least one further DC-isolated winding as a high-voltage winding.
8. The transformer as claimed in claim 7, wherein the transformer has a three-phase configuration.
9. A transformer comprising:
a transformer core;
at least one strip winding as claimed in claim 3 as a low-voltage winding; and
at least one further DC-isolated winding as a high-voltage winding.
10. The transformer as claimed in claim 9, wherein the transformer has a three-phase configuration.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula (I):
in which:
R1 is an aryl or heteroaryl group, optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-18)alkyl, C(1-18)alkoxy, C(1-18)alkylthio, arylC(1-18)alkoxy, hydroxy, halogen, CN, COR6, carboxy, COOR6, CONR9R10, NR6COR7, SO2NR9R10, NR6SO2R7, NR9R10, mono to perfluoro-C(1-4)alkyl and mono to perfluoro-C(1-4)alkoxy, oxo, CH2COOH or a salt thereof, CH2COOR8, CH2CONR9R10, CH2CN, (CH2)mNR9R10, (CH2)mOH or (CH2)mOR6 where m is an integer from 1 to 3;
R2 is an aryl or heteroaryl group, optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-18)alkyl, C(1-18)alkoxy, C(1-18)alkylthio, arylC(1-18)alkoxy, hydroxy, halogen, CN, COR6, carboxy, COOR6, CONR9R10, NR6COR7, SO2NR9R10, NR6SO2R7, NR9R10, mono to perfluoro-C(1-4)alkyl, mono to perfluoro-C(1-4)alkoxy, and arylC(1-4)alkyl;
R3 is hydrogen or C(1-4)alkyl which may be unsubstituted or substituted by hydroxy, OR6, COR6, carboxy, COOR6, CONR9R10, NR9R10, mono- or di-(hydroxyC(1-6)alkyl)amino or N-hydroxyC(1-6)alkyl-N-C(1-6)alkyl amino;
R4 is an aryl or a heteroaryl ring optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-18)alkyl, C(1-18)alkoxy, C(1-18)alkylthio, arylC(1-18)alkoxy, hydroxy, halogen, CN, COR6, carboxy, COOR6, CONR9R10, NR6COR7, SO2NR9R10, NR6SO2R7, NR9R10, mono to perfluoro-C(1-4)alkyl and mono to perfluoro-C(1-4)alkoxy;
R5 is an aryl ring which is further optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C1-18)alkyl, C(1-18)alkoxy, C(1-18)alkylthio, arylC(1-18)alkoxy, hydroxy, halogen, CN, COR6, carboxy, COOR6, CONR9R10, NR6COR7, SO2NR9R10, NR6SO2R7, NR9R10, mono to perfluoro-C(1-4)alkyl and mono to perfluoro-C(1-4)alkoxy;
R6 and R7 are independently hydrogen or C(1-20)alkyl, for instance C(1-4)alkyl (e.g. methyl or ethyl);
R8 is C(1-4)alkyl or a pharmaceutically acceptable in vivo hydrolysable ester group;
R9 and R10 which may be the same or different is each selected from hydrogen, C(1-12)alkyl, CH2R11, CHR12CO2H or a salt thereof, or R9 and R10 together with the nitrogen to which they are attached form a 4- to 7-, preferably 5- to 7-, membered ring optionally containing one or more further heteroatoms selected from oxygen, nitrogen and sulphur, and optionally substituted by one or two substituents selected from hydroxy, oxo, C(1-4)alkyl, C(1-4)alkylCO, or aryl;
R11 is COOH or a salt thereof, COOR8, CONR6R7, CN, CH2OH or CH2OR6;
R12 is an amino acid side chain;
n is an integer from 1 to 4, preferably 1 or 3;
X is O or S; and
Z is CR13R14 where R13 and R14 are each hydrogen or C(1-4)alkyl, or R13 and R14 together with the intervening carbon atom form a C(3-6)cycloalkyl ring.
2. A compound of formula (I) as claimed in claim 1 in which Z is CH2.
3. A compound of formula (I) as claimed in claim 1 in which R1 is an aryl group selected from phenyl and naphthyl or a heteroaryl group which comprises a 5- or 6- membered, monocyclic heteroaryl group comprising 1 or 2 nitrogen heteroatoms.
4. A compound of formula (I) as claimed in claim 1 in which R1 is pyrimidyl optionally substituted by 1 or 2 substituents selected from oxo, arylC(1-4)alkyl, C(1-6)alkyl, C(3-6)cycloalkyl, hydroxy, C(1-4)alkoxy, carboxyC(1-6)alkyl, C(1-6)alkylcarboxyC(1-6)alkyl, di-C(1-6)alkylamino, and morpholino; or pyrazolyl optionally substituted by C(1-6)alkyl.
5. A compound as claimed in claim 4 in which ZR1 is pyrimid-5-ylmethyl optionally substituted by 2-methoxy, 2-trifluoromethyl, 2-(4-morpholino) or 2-dimethylamino; 2-oxo-pyrimid-5-ylmethyl or 1-methyl-4-pyrazolylmethyl.
6. A compound of formula (I) as claimed in claim 1 in which X is S.
7. A compound of formula (I) as claimed in claim 1 in which R2 is an aryl group selected from phenyl and naphthyl or a heteroaryl group selected from pyridyl, pyrimidinyl, pyrazolyl, furanyl, thienyl, thiazolyl, quinolyl, benzothiazolyl, pyridazolyl and pyrazinyl.
8. A compound of formula (I) as claimed in claim 7 in which R2 is phenyl optionally substituted by halogen.
9. A compound of formula (I) as claimed in claim 1 in which R3 is selected from hydrogen; and methyl, ethyl and propyl, optionally substituted by amino, C(1-3)alkylamino, di C(1-3)alkylamino, hydroxyC(1-3)alkylamino, hydroxy, C(1-3)alkoxy, carboxy, C(1-3)alkylcarboxy, and heterocycyl.
10. A compound of formula (I) as claimed in claim 1 in which R4 is selected from phenyl optionally substituted by halogen; thiophene; pyridine; and pyrimidine.
11. A compound of formula (I) as claimed in claim 1 in which R5 is phenyl optionally substituted by halogen, trifluoromethyl, or trifluoromethoxy.
12. A compound of formula (I) as claimed in claim 10 in which R4 and R5 together form a 4-(phenyl)phenyl substituent in which the remote phenyl ring may be optionally substituted by halogen or trifluoromethyl.
13. A compound of formula (I) as claimed in claim 1 selected from the group consisting of:
1-(N-methyl-N-(4-(4-chlorophenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-methylpyrazol-4-ylmethyl)pyrimidin-4-one;
1-(N-methyl-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(1-methylpyrazol-4-ylmethyl)pyrimidin-4-one;
1-(N-(2-dimethylaminoethyl)-N-(4-(4-chlorophenyl)benzyl)aminocarbonyl methyl)-2-(4-fluorobenzyl)thio-5-(1-methylpyrazol-4-ylmethyl)pyrimidin-4-one;
1-(N-methyl-N-(4-(4-chlorophenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(2-(4-morpholino)pyrimid-5-ylmethyl)pyrimidin-4-one;
1-(N-(2-(dimethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)amino carbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one;
1-(N-(2-(diethylamino)ethyl)-N-(4-(4-chlorophenyl)benzyl)aminocarbonyl methyl)-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one;
1-(N-(2-(diethylamino)ethyl)-N-(2-(4-trifluoromethylphenyl)pyrid-5-ylmethyl) aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one;
1-(N-(2-(1-piperidino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)amino carbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one bitartrate;
1-(N-(carboxymethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonyl methyl)-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one sodium salt; or
a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 13 and a pharmaceutically acceptable carrier.
15. A method of treating atherosclerosis which method comprises administering to a patient in need thereof an effective amount of a compound of formula (I) as claimed in claim 1 and a statin.
16. A process for preparing a compound of formula (I)
in which:
R1 is an aryl or heteroaryl group, optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-18)alkyl, C(1-18)alkoxy, C(1-18)alkylthio, arylC(1-18)alkoxy, hydroxy, halogen, CN, COR6, carboxy, COOR6, CONR9R10, NR6COR7, SO2NR9R10, NR6SO2R7, NR9R10, mono to perfluoro-C(1-4)alky and mono to perfluoro-C(1-4)alkoxy, oxo, CH2COOH or a salt thereof, CH2COOR8, CH2CONR9R10, CH2CN, (CH2)mNR9R10, (CH2)mOH or (CH2)mOR6 where m is an integer from 1 to 3;
R2 is an aryl or heteroaryl group, optoinally substituted 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-18)alkyl, C(1-18)alkoxy, C(1-18)alkylthio, arylC(1-18)alkoxy, hydroxy, halogen, CN, COR6, carboxy, COOR6, CONR9R10, NR6COR7, SO2NR9R10, NR6SO2R7, NR9R10, mono to perfluoro-C(1-4)alkyl, mono to perfluoro-C(1-4)alkoxy, and arylC(1-4)alkyl;
R3 is hydrogen or C(1-4)alkyl which may be unsubstituted or substituted by hydroxy, OR6, COR6, carboxy, COOR6, CONR9R10, NR9R10, mono- or di-(hydroxyC(1-6)alkyl)amino or N-hydroxyC(1-6)alkyl-N-C(1-6)alkyl amino;
R4 is an aryl or a heteroaryl ring optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-18)alkyl, C(1-18)alkoxy, C(1-18)alkylthio, arylC(1-18)alkoxy, hydroxy, halogen, CN, COR6, carboxy, COOR6, CONR9R10, NR6COR7, SO2NR9R10, NR6SO2R7, NR9R10, mono to perfluoro-C(1-4)alkyl and mono to perfluoro-C(1-4)alkoxy;
R5 is an aryl ring which is further optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-18)alkyl, C(1-18)alkoxy, C(1-18)alkylthio, arylC(1-18)alkoxy, hydroxy, halogen, CN, COR6, carboxy, COOR6, CONR9R10, NR6COR7, SO2NR9R10, NR6SO2R7, NR9R10, mono to perfluoro-C(1-4)alkyl and mono to perfluoro-C(1-4)alkoxy;
R6 and R7 are independently hydrogen or C(1-20)alkyl, for instance C(1-4)alkyl (e.g. methyl or ethyl);
R8 is C(1-4)alkyl or a pharmaceutically acceptable in vivo hydrolysable ester group;
R9 and R10 which may be the same or different is each selected from hydrogen, C(1-12)alkyl, CH2R11, CHR12CO2H or a salt thereof, or R9 and R10 together with the nitrogen to which they are attached form a 4- to 7-, preferably 5- to 7-, membered ring optionally containing one or more further heteroatoms selected from oxygen, nitrogen and sulphur, and optionally substituted by one or two substituents selected from hydroxy, oxo, C(1-4)alkyl, C(1-4)alkylCO, or aryl;
R11 is COOH or a salt thereof, COOR8, CONR6R7, CN, CH2OH or CH2OR6;
R12 is an amino acid side chain;
n is an integer from 1 to 4, preferably 1 or 3;
X is O or S; and
Z is CR13R14 where R13 and R14 are each hydrogen or C(1-4)alkyl, or R13 and R14 together with the intervening carbon atom form a C(3-6)cycloalkyl ring;
which process comprises:
(a) reacting a compound of formula (II):
in which X, Y, Z, R1 and R2 are the same as defined herein above for formula (I),
with a compound of formula (III):
R5\u2014R4\u2014CH2NHR3\u2003\u2003(III)
in which R3, R4 and R5 are the same as defined herein above for formula (I); under amide forming conditions;
(b) reacting a compound of formula (IV):
in which X, Z, R1 and R2 are the same as defined herein above for formula (I), with a compound of formula (V):
R5\u2014R4\u2014CH2NR3\u2014CO\u2014(CH2)n-L1\u2003\u2003(V)
in which n, R3, R4 and R5 are the same as defined herein above for formula (I), and L1 is a leaving group such as halogen; in the presence of a base such as a secondary or tertiary amine, in an inert solvent;
(c) when X is S, reacting a compound of formula (VI):
in which n, Z, R1, R3, R4 and R5 are the same as defined herein above for formula (I), with a compound of formula (VII):
R2\u2014CH2-L1\u2003\u2003(VII)
in which R2 and L1 are the same as defined herein above for formula (I),
in the presence of a base such as a secondary or tertiary amine, in an inert solvent; or
(d) when X is O, reacting a compound of formula (VIII):
in which n, Z, R1, R3, R4 and R5 are the same as defined herein above for formula (I), and L2 is a leaving group,
with a compound of formula (IX):
R2\u2014CH2\u2014OH\u2003\u2003(IX)
in which R2 is the same as defined herein above for formula (I), in the presence of a base, in an inert solvent.
17. A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1 and a pharmaceutically acceptable carrier.
18. A method of treating atherosclerosis which method comprises administering to a patient in need thereof an effective amount of a compound of formula (I) as claimed in claim 1 to a patient in need thereof.